The PROSERA Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of the oral Inhalation of seralutinib for the treatment of pulmonary arterial hypertension is currently enrolling.
The PROSERA study’s objective is to understand the effect of seralutinib on specific pathways in the body that lead to the inflammation, proliferation and fibrosis associated with pulmonary arterial hypertension. Currently there is no treatment available that targets these specific pathways collectively.
This study is designed to see if, by blocking these pathways, seralutinib can prevent or reverse the effects of pulmonary arterial hypertension when added to currently approved therapies. It is produced as a fine dry powder to be inhaled using a small hand-held device.
The information about the Phase 3 PROSERA study on the Gossamer Bio website includes:
- easy-to-understand, patient friendly explanations about the study
- an excellent educational video with Prof Luke Howard, a pulmonary arterial hypertension expert from the UK
- a list of study locations, with map: the list of activated sites is regularly updated on both the PROSERA.com website and on clinicaltrials.gov, so it’s best to check on a regular basis
- a list of patient support groups, with map
Check out also the clinicaltrials.gov website, last updated on March 18, 2024, at this link
And the poster presented at the recent Pulmonary Vascular Research Institute’s annual congress at this link
The results of the previous study on seralutinib, the Phase 2 TORREY clinical trial, were reported on this platform in an article published in December 2022 (check this link)